

**Omega-3 ethyl esters (Lovaza®)
Vascepa® (icosapent ethyl)
Effective 11/26/18**

Plan	<input checked="" type="checkbox"/> MassHealth <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	N/A		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Lovaza and Vascepa are types of omega 3 fatty acids indicated as adjuncts to diet to reduce triglyceride levels in adults with severe hypertriglyceridemia. Vascepa is also indicated as an adjunct to statin therapy to reduce the risk of myocardial infarction, coronary revascularization, and unstable angina requiring hospitalization in adults with elevated triglycerides.

Coverage Guidelines

Approval will be granted if the member meets the following drug specific criteria:

Omega-3-acid ethyl esters (Lovaza®):

1. The member has a diagnosis of severe hypertriglyceridemia (≥ 500 mg/dL) **AND**
2. Patient is new to AllWays Health Partners and has been stabilized on omega-3-acid ethyl esters (Lovaza®) **AND**
3. The member will maintain a lipid-lowering diet and exercise regimen during treatment **OR**
 1. The member has a diagnosis of severe hypertriglyceridemia (≥ 500 mg/dL) **AND**
 2. The member has had a documented side effect, allergy, or treatment failure with a minimum of one agent from *each* of the following categories:
 - a. Fibric acid derivatives (e.g. fenofibrate, gemfibrozil, etc.)
 - b. Long-acting niacin agents (e.g. niacin ER, Niaspan®, etc.)
 - c. HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin, rosuvastatin, etc.)**AND**
 3. The member will maintain a lipid-lowering diet and exercise regimen during treatment



Vascepa® (icosapent ethyl):

1. The member has a diagnosis of severe hypertriglyceridemia (≥ 500 mg/dL) **AND**
 2. The member is new to AllWays Health Partners and has been stabilized on omega-3-acid ethyl esters (**Vascepa®**) **AND**
 3. The member will maintain a lipid-lowering diet and exercise regimen during treatment
- OR**
1. The member has a diagnosis of severe hypertriglyceridemia (≥ 500 mg/dL) **AND**
 2. The member has had a documented side effect, allergy, or treatment failure with a minimum of one agent from *each* of the following categories:
 - a. Fibric acid derivatives (e.g. fenofibrate, gemfibrozil, etc.)
 - b. Long-acting niacin agents (e.g. niacin ER, Niaspan®, etc.)
 - c. HMG-CoA reductase inhibitors (e.g. simvastatin, atorvastatin, rosuvastatin, etc.)
- AND**
3. The member has had a documented side effect, allergy, or treatment failure with omega-3-acid ethyl esters (Lovaza®)
 4. The member will maintain a lipid-lowering diet and exercise regimen during treatment

Limitations

Approvals will be granted for a duration of 3 years (36 months)

References

1. Omega-3 fatty acids [prescribing information]. Tempe, AZ: Century HealthCare Inc; received July 2018
2. Lovaza (omega-3-acid ethyl esters) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; September 2015.
3. Vascepa (icosapent ethyl) [prescribing information]. Bedminster, NJ: Amarin Pharma Inc; February 2017.
4. Siscovick DS, Barringer TA, Fretts AM, et al; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. *Circulation*. 2017;135(15):e867-e884.[PubMed 28289069]10.1161/CIR.0000000000000482
5. Jacobson TA, Maki KC, Orringer CE, et al; NLA Expert Panel. National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 2 [published correction appears in *J Clin Lipidol*. 2016;10(1):211]. *J Clin Lipidol*. 2015;9(6)(suppl):S1-S122.[PubMed 26699442
6. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2012;97(9):2969-2689.[PubMed 22962670]

Review History

2013: Implemented

11/2016: Reviewed P&T

11/20//2017: Updated P&T

11/26/2018: Reviewed P&T

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.

